Beyond Medical Provides Corporate Update

Beyond Medical Provides Corporate Update

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") is pleased to provide a corporate update on its medical face mask manufacturing subsidiary Micron Technologies Inc. ("Micron Technologies").

The Company is reviewing Micron Technologies' medical face mask manufacturing business as many jurisdictions have recently lifted mask mandates and as demand for face masks rapidly declines. The Company is considering operating Micron Technologies' facility at reduced capacity or potentially terminating its mask manufacturing business via a sale of all inventory and equipment related to its mask manufacturing business and to seek new business opportunities.

As reported by the Company in its interim financial statements for the nine months ended September 30, 2021, the Company had cash and cash equivalents of $1,646,174 and total liabilities of $420,541. The Company expects to file its annual financial statements in the coming weeks. Readers are advised to carefully review the entirety of the Company's current filings at www.SEDAR.com.

Kal Malhi, the Company's C.E.O., commented: "The Company is interested in investigating business opportunities in sectors which can offer attractive shareholder returns and offer growth opportunities with the infusion of capital. We are currently reviewing several opportunities and will provide updates as our investigations progress. We cannot, however, provide any assurance the Company will successfully identify, secure and fund an agreement to purchase either a business or asset on favorable terms or at all."

Kal Malhi further commented: "The Company welcomes submissions of any opportunities from entrepreneurs and institutional investors where the Company's current capital and ability to raise additional capital can leverage growth for a business."

On behalf of the Board of Directors

"Kal Malhi"
President, CEO and Director
Email: kal@bullruncapital.ca

FORWARD LOOKING STATEMENTS:

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/116378

News Provided by Newsfile via QuoteMedia

DOCT:CNX
The Conversation (0)
beyond medical

Beyond Medical Technologies

Keeping Canadians Healthy and Safe

Beyond Medical Technologies Announces Marketing Initiatives

Beyond Medical Technologies Announces Marketing Initiatives

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to announce that it has entered into an online marketing agreement ("AGORA Agreement") with AGORA Internet Relations Corp. ("AGORA") and an investor marketing agreement (the "INN Agreement")... Keep Reading...
Beyond Medical Subsidiary Micron Technologies Achieves "Amazon's Choice" Designation and Begins to Accept Bitcoin Payments for its Made in Canada Face Masks

Beyond Medical Subsidiary Micron Technologies Achieves "Amazon's Choice" Designation and Begins to Accept Bitcoin Payments for its Made in Canada Face Masks

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies "). "Amazon's Choice" Designation for Medical Grade... Keep Reading...
Beyond Medical Manufactures N95 Medical Face Masks as Third Wave of COVID-19 Surges

Beyond Medical Manufactures N95 Medical Face Masks as Third Wave of COVID-19 Surges

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies "). Manufacturing Three-Ply Medical Grade Face Masks... Keep Reading...
Beyond Medical subsidiary Micron Technologies begins Sales of Made in Canada Face Masks to Walmart

Beyond Medical subsidiary Micron Technologies begins Sales of Made in Canada Face Masks to Walmart

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies "). Products Now Available at Walmart Micron... Keep Reading...
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News